Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ProKidney Corp. (PROK : NSDQ)

• Company Description    ProKidney LP is a late clinical-stage cellular therapeutics company focused on CKD. The company's lead product candidate includes REACT(TM) is a first-of-its-kind, patented disease-modifying autologous cellular therapy. ProKidney LP, formerly known as Suvretta Holdings Corp. III, is based in WINSTON-SALEM, N,C. Number of Employees: 231

• Price / Volume Information    Yesterday's Closing Price: $1.75 Daily Weekly Monthly 20 Day Moving Average: 768,944 shares Shares Outstanding: 301.92 (millions) Market Capitalization: $528.35 (millions) Beta: 1.70 52 Week High: $7.13 52 Week Low: $0.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -12.50% -16.77% 12 Week -21.52% -27.45% Year To Date -21.88% -28.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2000 FRONTIS PLAZA BLVD SUITE 250 - WINSTON-SALEM,NC 27103 USA ph: 336-999-7019 fax: - daniel@lifesciadvisors.com http://www.prokidney.com

• General Corporate Information    Officers Bruce Culleton - Chief Executive Officer and Director Pablo Legorreta - Chairman James Coulston - Chief Financial Officer William F. Doyle - Director Jennifer Fox - Director Peer Information ProKidney Corp. (GSAC) ProKidney Corp. (CASIF) ProKidney Corp. (ALCD.) ProKidney Corp. (OMNN) ProKidney Corp. (CGPI.) ProKidney Corp. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74291D104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 301.92 Most Recent Split Date: (:1) Beta: 1.70 Market Capitalization: $528.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 594.32 EPS Growth vs. Year Ago Period: -7.69% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -1.74% vs. Previous Quarter: 0.44% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -21.39 12/31/25 - -18.83 09/30/25 - -18.09 Current Ratio 03/31/26 - 9.06 12/31/25 - 9.13 09/30/25 - 10.32 Quick Ratio 03/31/26 - - 12/31/25 - 9.13 09/30/25 - 10.32 Operating Margin 03/31/26 - -8,131.50 12/31/25 - -7,725.20 09/30/25 - -9,547.45 Net Margin 03/31/26 - -8,131.50 12/31/25 - -7,725.20 09/30/25 - -9,547.45 Pre-Tax Margin 03/31/26 - -17,599.32 12/31/25 - -16,931.47 09/30/25 - -20,906.18 Book Value 03/31/26 - -3.39 12/31/25 - -3.36 09/30/25 - -3.41 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©